Denali Therapeutics (DNLI)

Denali Therapeutics Stock Price & Analysis


DNLI Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$20.24 - $48.46
Previous Close$30.94
Average Volume (3M)828.46K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$1.11B
Total Debt (Recent Filing)$62.05M
Price to Earnings (P/E)-12.6
Next EarningsNov 02, 2023
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-2.46
Shares Outstanding135,813,668
Standard Deviation0.20
10 Day Avg. Volume600,319
30 Day Avg. Volume828,463
Price to Book (P/B)5.18
Price to Sales (P/S)37.37
Price to Cash Flow (P/CF)10.60
P/FCF Ratio-16.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside100.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Denali Therapeutics’s price range in the past 12 months?
Denali Therapeutics lowest stock price was $20.24 and its highest was $48.46 in the past 12 months.
    What is Denali Therapeutics’s market cap?
    Currently, no data Available
    When is Denali Therapeutics’s upcoming earnings report date?
    Denali Therapeutics’s upcoming earnings report date is Nov 02, 2023 which is in 330 days.
      How were Denali Therapeutics’s earnings last quarter?
      Denali Therapeutics released its earnings results on Nov 03, 2022. The company reported -$0.84 earnings per share for the quarter, missing the consensus estimate of -$0.802 by -$0.038.
        Is Denali Therapeutics overvalued?
        According to Wall Street analysts Denali Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Denali Therapeutics pay dividends?
          Denali Therapeutics does not currently pay dividends.
          What is Denali Therapeutics’s EPS estimate?
          Denali Therapeutics’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Denali Therapeutics have?
          Denali Therapeutics has 135,813,670 shares outstanding.
            What happened to Denali Therapeutics’s price movement after its last earnings report?
            Denali Therapeutics reported an EPS of -$0.84 in its last earnings report, missing expectations of -$0.802. Following the earnings report the stock price went down -7.542%.
              Which hedge fund is a major shareholder of Denali Therapeutics?
              Among the largest hedge funds holding Denali Therapeutics’s share is Flagship Pioneering Inc.. It holds Denali Therapeutics’s shares valued at 80M.


                Denali Therapeutics Stock Smart Score

                The Denali Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Denali Therapeutics

                Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Mirati Therapeutics
                Cerevel Therapeutics Holdings

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis